[go: up one dir, main page]

MX2023002589A - Derivados de fumagilol y polimorfos de los mismos. - Google Patents

Derivados de fumagilol y polimorfos de los mismos.

Info

Publication number
MX2023002589A
MX2023002589A MX2023002589A MX2023002589A MX2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A MX 2023002589 A MX2023002589 A MX 2023002589A
Authority
MX
Mexico
Prior art keywords
polymorphs
derivatives
fumargilol
fumagyl
aminocyclohexyl
Prior art date
Application number
MX2023002589A
Other languages
English (en)
Inventor
John S Petersen
Original Assignee
Syndevrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndevrx Inc filed Critical Syndevrx Inc
Publication of MX2023002589A publication Critical patent/MX2023002589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/31—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals in which the oxirane rings are condensed with a carbocyclic ring system having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a sales y polimorfos de carbamatos de aminoalquilfumagilol (por ejemplo, sal de ácido bencenosulfónico de N-(trans-4-aminociclohexil)carbamato de fumagil-6-ilo y sal de ácido hidroxinaftoico de N-(trans-4-aminociclohexil)carbamato de fumagil-6-ilo). Los polimorfos se caracterizan por difracción de polvo de rayos X, calorimetría de exploración diferencial y análisis termogravimétrico, entre otros métodos. Los polimorfos y sales pueden usarse como intermediarios en la producción de derivados de fumagilol (por ejemplo, derivados de fumagilol conjugados con polímero) así como agentes terapéuticos para el tratamiento de varias enfermedades y condiciones tales como cáncer.
MX2023002589A 2015-12-10 2018-06-06 Derivados de fumagilol y polimorfos de los mismos. MX2023002589A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265675P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
MX2023002589A true MX2023002589A (es) 2023-03-22

Family

ID=57589276

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018006904A MX2018006904A (es) 2015-12-10 2016-12-09 Derivados de fumagilol y polimorfos de los mismos.
MX2023002589A MX2023002589A (es) 2015-12-10 2018-06-06 Derivados de fumagilol y polimorfos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018006904A MX2018006904A (es) 2015-12-10 2016-12-09 Derivados de fumagilol y polimorfos de los mismos.

Country Status (11)

Country Link
US (2) US9969722B2 (es)
EP (1) EP3386956B1 (es)
JP (2) JP7553224B2 (es)
KR (2) KR102849342B1 (es)
CN (1) CN108290853B (es)
AU (1) AU2016366306B2 (es)
CA (1) CA3005450A1 (es)
DK (1) DK3386956T3 (es)
ES (1) ES2893749T3 (es)
MX (2) MX2018006904A (es)
WO (1) WO2017100553A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
MX386958B (es) 2013-04-10 2025-03-19 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y métodos de tratamiento de la obesidad.
DK3386956T3 (da) * 2015-12-10 2021-10-11 Syndevrx Inc Fumagillolderivater og polymorfer deraf
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
WO2024040009A2 (en) * 2022-08-17 2024-02-22 Primetime Life Sciences, Llc Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100581443B1 (ko) 1998-05-22 2006-05-23 다이이찌 세이야꾸 가부시기가이샤 약물복합체
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
CA2348931A1 (en) 1998-10-30 2000-05-11 Daiichi Pharmaceutical Co., Ltd. Dds compound and method for measurement thereof
AU7025600A (en) 1999-09-08 2001-04-10 School Of Pharmacy, University Of London, The Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
ATE440094T1 (de) 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
WO2003070173A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7332523B2 (en) 2002-04-11 2008-02-19 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
CN102321584B (zh) 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
EP2170402B1 (en) 2007-06-26 2015-03-25 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
JP5557746B2 (ja) 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
EP2484681A1 (en) 2007-12-04 2012-08-08 Cadila Healthcare Limited Chemically and chirally pure gentisate salt of solifenacin
EP2244712B1 (en) 2008-01-22 2015-08-05 Thar Pharmaceuticals Inc. In vivo studies of crystalline forms of meloxicam
CN102105156B (zh) 2008-05-22 2016-05-25 特拉维夫大学拉莫特有限公司 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
TWI373345B (en) 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2011150088A1 (en) 2010-05-25 2011-12-01 SynDevRX Optimized drug conjugates
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) * 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
CA2829204C (en) 2011-03-08 2019-12-24 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
JP6177888B2 (ja) * 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
MX386958B (es) 2013-04-10 2025-03-19 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y métodos de tratamiento de la obesidad.
DK3386956T3 (da) * 2015-12-10 2021-10-11 Syndevrx Inc Fumagillolderivater og polymorfer deraf
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction

Also Published As

Publication number Publication date
EP3386956B1 (en) 2021-07-14
US9969722B2 (en) 2018-05-15
ES2893749T3 (es) 2022-02-10
JP2019501898A (ja) 2019-01-24
CN108290853B (zh) 2022-05-31
MX2018006904A (es) 2018-08-24
AU2016366306A1 (en) 2018-05-31
HK1258254A1 (zh) 2019-11-08
KR20250127347A (ko) 2025-08-26
KR20180093995A (ko) 2018-08-22
CA3005450A1 (en) 2017-06-15
KR102849342B1 (ko) 2025-08-21
EP3386956A1 (en) 2018-10-17
US20170166556A1 (en) 2017-06-15
AU2016366306B2 (en) 2021-02-25
JP7553224B2 (ja) 2024-09-18
CN108290853A (zh) 2018-07-17
US10287277B2 (en) 2019-05-14
WO2017100553A1 (en) 2017-06-15
DK3386956T3 (da) 2021-10-11
JP2024103495A (ja) 2024-08-01
US20180291010A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
MX2023002589A (es) Derivados de fumagilol y polimorfos de los mismos.
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
CL2017001572A1 (es) Compuestos de triazolopirimidina y usos de los mismos.
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
CR20150370A (es) Compuestos antivirales
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
BR112014005468A2 (pt) derivados de aminopiridina para uso como moduladores de atividade quinase
RU2021103000A (ru) Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MX388170B (es) Polimorfos de selinexor
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
ECSP14013215A (es) Compuestos novedosos
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
MX2020000976A (es) Compuestos abt universales y usos de los mismos.
CO7200270A2 (es) Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas
NI201500050A (es) Benzamidas
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
DOP2020000118A (es) Proceso para la preparación de derivados de quinolina
DOP2017000034A (es) Compuestos de imidazopiridazina
BR112016013618A8 (pt) derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos